INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY

Scope & Guideline

Advancing the Science of Psychopharmacology

Introduction

Immerse yourself in the scholarly insights of INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0268-1315
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Convergefrom 1986 to 2024
AbbreviationINT CLIN PSYCHOPHARM / Int. Clin. Psychopharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The journal 'INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY' primarily focuses on the advancements and challenges in psychopharmacology, emphasizing clinical implications and the treatment of various psychiatric disorders through pharmacological interventions. It serves as a platform for research that bridges the gap between laboratory findings and clinical practice.
  1. Clinical Efficacy and Safety of Psychopharmacological Interventions:
    The journal publishes studies that assess the efficacy and safety profiles of various psychopharmacological agents, including novel medications for mood disorders, schizophrenia, and treatment-resistant cases.
  2. Pharmacogenetics and Personalized Medicine:
    Research on pharmacogenetic analyses and therapeutic drug monitoring is a core focus, aiming to tailor antidepressant and antipsychotic treatments based on individual patient profiles.
  3. Psychiatric Comorbidities and Somatic Conditions:
    Papers often explore the interplay between psychiatric disorders and somatic health issues, such as metabolic syndrome and diabetes, which are crucial for comprehensive patient care.
  4. Innovative Treatment Strategies:
    The journal highlights innovative treatment approaches, including the use of long-acting injectable antipsychotics and adjunctive therapies, to improve adherence and outcomes in patients with severe mental illnesses.
  5. Case Reports and Observational Studies:
    The inclusion of case reports and observational studies provides insights into real-world applications of psychopharmacological treatments, contributing to evidence-based practice.
The recent publications in 'INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY' indicate a shift towards emerging themes that reflect current challenges and innovations in the field of psychopharmacology.
  1. Treatment-Resistant Depression:
    There is an increasing focus on innovative treatments for treatment-resistant depression, including the use of ketamine and esketamine, highlighting a shift towards exploring alternative therapies.
  2. Impact of Medical Comorbidities on Psychiatric Treatment:
    Recent studies are emphasizing the effects of medical comorbidities, such as diabetes and cardiovascular conditions, on psychiatric treatment outcomes, indicating a more integrated approach to patient management.
  3. Pharmacogenetic Approaches for Personalized Treatment:
    The trend towards personalized medicine in psychiatry is reflected in the growing number of studies focusing on pharmacogenetics and tailored treatment strategies based on genetic profiles.
  4. Long-Acting Injectable Antipsychotics:
    Research on long-acting injectable antipsychotics has gained momentum, particularly regarding their impact on treatment adherence and patient outcomes in severe mental illness.
  5. Neuroinflammation and Psychiatric Disorders:
    Emerging themes include the role of neuroinflammation in psychiatric disorders, exploring how inflammatory processes may contribute to the pathophysiology of conditions like depression and schizophrenia.

Declining or Waning

While the journal has consistently focused on several key areas of psychopharmacology, some themes appear to be declining in prominence based on recent publications.
  1. Traditional Antidepressant Therapies:
    Research on older classes of antidepressants, such as tricyclics and older SSRIs, seems to be waning as newer agents and innovative treatments gain more attention.
  2. Longitudinal Studies on Established Medications:
    There is a noticeable decrease in longitudinal studies examining the long-term effects of established medications, potentially overshadowed by newer treatment modalities and their rapid evaluation.
  3. Generalized Anxiety Disorders:
    Publications focusing specifically on generalized anxiety disorders and their pharmacological treatment have diminished, suggesting a shift towards more complex and treatment-resistant cases.
  4. Neuroleptic Malignant Syndrome Reports:
    Case reports and studies specifically addressing neuroleptic malignant syndrome and similar acute reactions have become less frequent, possibly due to improved awareness and management strategies.
  5. Focus on Non-Pharmacological Interventions:
    While there is some interest in the intersection of psychopharmacology and psychotherapy, the specific focus on non-pharmacological interventions appears to be less prominent in recent issues.

Similar Journals

Current Psychiatry Reports

Connecting clinicians and researchers in psychiatry.
Publisher: SPRINGERISSN: 1523-3812Frequency: 12 issues/year

Current Psychiatry Reports, published by Springer, is a premier academic journal dedicated to the dissemination of cutting-edge research in the field of psychiatry and mental health. With a significant impact factor reflecting its esteemed position at Q1 in Psychiatry, this journal ranks an impressive #35 out of 567 in its category, placing it within the 93rd percentile of psychiatric publications as per Scopus metrics. Since its inception in 1996, it has provided a vital platform for clinicians, researchers, and students to explore and discuss contemporary psychiatric issues, advancements, and methodologies. While Current Psychiatry Reports is a subscription-based journal, its robust scholarly contributions are invaluable for practitioners and scholars looking to stay abreast of developments and empirical studies that shape the field. Based in the United States, at ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY 10004, it remains an authoritative source for evidence-based insights that guide both research and clinical practice in mental health.

ACTA PSYCHIATRICA SCANDINAVICA

Connecting Global Minds in Psychiatric Research
Publisher: WILEYISSN: 0001-690XFrequency: 12 issues/year

ACTA PSYCHIATRICA SCANDINAVICA is a leading journal in the field of Psychiatry and Mental Health, published by Wiley since its inception in 1926. With a strong commitment to advancing psychiatric research, this esteemed journal boasts an impressive impact factor and ranks within the top 7% of its category, reflecting its influence and relevance in the field. Operating without an Open Access model, the journal serves as a vital resource for professionals, researchers, and students keen on accessing high-quality, peer-reviewed studies focused on mental health issues. The scope of ACTA PSYCHIATRICA SCANDINAVICA spans a broad spectrum of psychiatric topics, providing a platform for groundbreaking research and clinical practice insights. Based in the United Kingdom and featuring contributions from experts worldwide, the journal continues to shape the future of psychiatric research through its rigorous publication standards and commitment to scholarly excellence.

Journal of the Academy of Consultation-Liaison Psychiatry

Transforming Mental Health Understanding and Practice.
Publisher: ELSEVIER SCIENCE INCISSN: 2667-2960Frequency: 6 issues/year

The Journal of the Academy of Consultation-Liaison Psychiatry, published by Elsevier Science Inc, stands as a pivotal resource in the fields of clinical psychology and psychiatry, with a commendable impact factor that reflects its significance in mental health research. Established in 2021, this journal has rapidly ascended within its domain, achieving a Q2 category ranking in both Clinical Psychology and Psychiatry and Mental Health as of 2023, placing it among the top journals in these fields. With a Scopus ranking of 64 out of 311 in clinical psychology and 163 out of 567 in psychiatry, it serves as an essential platform for researchers, professionals, and students to access high-quality articles that advance knowledge and practices in consultation-liaison psychiatry. The journal promotes open access initiatives, enhancing the reach and impact of its publications, and is committed to disseminating innovative research findings that contribute to improving patient care and understanding of mental health complexities. Whether you are engaged in academic, clinical, or applied research, the Journal of the Academy of Consultation-Liaison Psychiatry is your go-to source for evidence-based insights and groundbreaking studies.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Empowering Professionals with Essential Findings in Mental Health Treatment
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0271-0749Frequency: 6 issues/year

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, an esteemed publication from Lippincott Williams & Wilkins, serves as a vital resource in the fields of pharmacology and psychiatry. With a notable Q2 ranking in both the medical pharmacology and psychiatry categories, this journal facilitates the dissemination of significant findings related to psychopharmacological research, clinical practices, and advancements in mental health treatment. The journal has been committed to publishing high-quality, peer-reviewed articles since its inception in 1981, covering a wide scope of topics crucial for professionals, researchers, and students alike. With a current impact factor and burgeoning interest from the academic community, the JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY is essential for anyone engaged in the study or practice of clinical psychopharmacology, providing insights that shape contemporary psychiatric medication strategies and improve patient outcomes. For access, please refer to the official publication channels.

Psychiatria i Psychologia Kliniczna-JOURNAL OF PSYCHIATRY AND CLINICAL PSYCHOLOGY

Championing open access to impactful mental health research.
Publisher: MEDICAL COMMUNICATIONSISSN: 1644-6313Frequency: 4 issues/year

Psychiatria i Psychologia Kliniczna - Journal of Psychiatry and Clinical Psychology is a vital platform for advancing the fields of psychiatry and clinical psychology, published by Medical Communications in Poland. With its ISSN 1644-6313, this Open Access journal has been providing unrestricted access to impactful research since 2005, ensuring that findings in mental health are both accessible and disseminated widely. Although currently ranked in the Q4 quartile across Clinical Psychology and Psychiatry and Mental Health categories, and with the Scopus ranks placing it at 262/311 in Clinical Psychology and 493/567 in Psychiatry, the journal serves as a crucial resource for researchers seeking to explore innovative methodologies and therapeutic interventions. The journal's aim is to enhance understanding and treatment of psychiatric disorders by facilitating the exchange of knowledge between academia and clinical practice. As it converges from 2006 to 2024, Psychiatria i Psychologia Kliniczna remains committed to publishing high-quality articles that contribute toward the evolving landscape of mental health research.

Turkish Journal of Endocrinology and Metabolism

Exploring New Frontiers in Endocrinology and Metabolic Disorders
Publisher: AVESISSN: 1301-2193Frequency: 4 issues/year

The Turkish Journal of Endocrinology and Metabolism, published by AVES, is a prominent platform dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. As an Open Access journal since 2002, it provides unrestricted access to its content, fostering a global exchange of knowledge among researchers, clinicians, and students. Operating from Turkey, this journal plays a crucial role in disseminating innovative findings related to endocrine disorders and metabolic diseases. While its current Q4 quartile rankings in both Endocrinology and Internal Medicine underscore areas for growth, they also signify the journal’s commitment to enhancing its impact within these disciplines. The journal emphasizes the development of locally relevant research while encouraging international contributions, thus bridging gaps in global health discourse. Engage with cutting-edge research that shapes clinical practices and informs public health policies by submitting your work or exploring the journal’s vast archive from 2009 to 2023.

Journal of Psychiatric Practice

Exploring innovative practices in psychiatry and mental health.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1527-4160Frequency: 6 issues/year

Journal of Psychiatric Practice, published by Lippincott Williams & Wilkins, is a premier journal dedicated to advancing the field of psychiatry and mental health. With a focus on evidence-based clinical practice, the journal has been a respected resource since its inception, providing a platform for a wide range of articles, including original research, reviews, and case reports from 1997 to the present. As of 2023, it holds a Q3 ranking in Psychiatry and Mental Health, reflecting its influential role in the academic community. The Journal is aimed at researchers, mental health professionals, and students, promoting the dissemination of essential knowledge and innovative practices. Subscribers benefit from the latest findings and discussions in the field while contributing to the ongoing advancements in psychiatric care. Although not classified as open access, the journal ensures wide accessibility to its valuable content, further solidifying its commitment to the mental health discipline.

Psychiatry and Clinical Psychopharmacology

Advancing Mental Health Through Innovative Research
Publisher: AVESISSN: 2475-0573Frequency: 4 issues/year

Psychiatry and Clinical Psychopharmacology, an open-access journal published by AVES since 2017, is dedicated to advancing the fields of psychiatric medicine and psychopharmacology. With an ISSN of 2475-0573 and an E-ISSN of 2475-0581, this journal aims to provide a platform for disseminating innovative research and clinical findings relevant to mental health professionals and researchers. Although it currently holds a Q3 ranking in Pharmacology (medical) and a Q4 ranking in Psychiatry and Mental Health according to the 2023 category quartiles, the journal has established itself as a significant contributor to evolving discussions in these critical fields. Based in the United Kingdom, the journal encompasses diverse topics, ranging from pharmacological treatments to novel therapeutic approaches in psychiatry, thereby appealing to a broad audience of clinicians, scientists, and students. The open-access model ensures that all research is readily available, fostering an environment of collaboration and knowledge-sharing as the journal converges until 2024 to encompass the latest advancements in both pharmacology and clinical psychopharmacology.

Therapeutic Advances in Psychopharmacology

Empowering Minds Through Accessible Knowledge
Publisher: SAGE PUBLICATIONS LTDISSN: 2045-1253Frequency: 1 issue/year

Therapeutic Advances in Psychopharmacology is a leading open-access journal published by SAGE Publications Ltd, focusing on the dynamic integration of pharmacological therapies and psychological health. Since its inception in 2011, this journal has made a significant impact on the fields of pharmacology and psychiatry, consistently earning a Q1 ranking in both categories as of 2023, reflecting its esteemed position within the scientific community. With an impressive Scopus rank placing it in the top 15% across relevant disciplines, the journal serves as a vital platform for researchers, professionals, and students eager to explore cutting-edge advancements in psychopharmacology. The open-access model, established in 2019, ensures that groundbreaking research is accessible to a wide audience, fostering collaboration and innovation in therapeutic strategies for mental health disorders. Through the dissemination of high-quality research and reviews, Therapeutic Advances in Psychopharmacology is committed to advancing understanding and practice within this critical field.

BIPOLAR DISORDERS

Elevating Discourse in Biological Psychiatry
Publisher: WILEYISSN: 1398-5647Frequency: 8 issues/year

BIPOLAR DISORDERS, published by Wiley, is a leading international journal dedicated to advancing the understanding and treatment of bipolar disorders. Since its establishment in 1999, the journal has become a vital resource in the fields of Biological Psychiatry and Psychiatry and Mental Health, currently ranked in the Q2 category for Biological Psychiatry and Q1 for Psychiatry and Mental Health as of 2023. With impressive Scopus rankings, it stands at 75th out of 567 in Psychiatry and Mental Health and 11th out of 51 in Biological Psychiatry, reflecting its influential role in shaping mental health research. The journal not only focuses on empirical studies, reviews, and clinical reports but also encourages innovative methodological advancements in understanding bipolar disorders. Although it does not offer Open Access, its extensive coverage from 1999 to 2024 ensures that practitioners, researchers, and students have access to a wealth of knowledge critical for the development of effective therapeutic interventions. For those engaging with cutting-edge research in psychiatric care, BIPOLAR DISORDERS serves as an essential platform for knowledge dissemination and academic discourse.